S.-B. Kim

Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study

Christian Jackisch, S.-B. Kim, Semiglazov Vf et al. · Annals of Oncology · 2014 · 112 citations · Full text

Medicine, Oncology, Pharmacokinetics +15

Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01)

Cristina Saura, Shanu Modi, Ian E. Krop et al. · Annals of Oncology · 2023 · 108 citations · Full text

Medicine, Oncology, Pharmacology +16

Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial

Ye Guo, Myung‐Ju Ahn, Anthony T.�C. Chan et al. · Annals of Oncology · 2019 · 58 citations · Full text

Medicine, Oncology, Pharmacotherapy +10

Overall survival (OS) in KATE2, a phase II study of programmed death ligand 1 (PD-L1) inhibitor atezolizumab (atezo)+trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+ advanced breast cancer (BC)

Leisha A. Emens, Francisco J. Esteva, Mark Beresford et al. · Annals of Oncology · 2019 · 55 citations · Full text

Medicine, Oncology, Pharmacology +17

Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia

Yanshuo Cao, Shukui Qin, Suxia Luo et al. · ESMO Open · 2021 · 55 citations · Full text

Medicine, Oncology, Pharmacotherapy +17